Skip to main content
SpringerLink
Log in

Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag

Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

An Erratum to this article was published on 24 June 2019

This article has been updated

Zusammenfassung

Die Behandlung des metastasierten Prostatakarzinoms (mPC) erlebt derzeit einen Paradigmenwechsel. Verschiedene randomisierte Phase-III-Studien konnten zeigen, dass die Chemotherapie mit Taxanen das Überleben der Patienten mit mPC signifikant verlängert. Das gilt sowohl für die metastasierte Erkrankung in der Kastrationsresistenz (metastasiertes kastrationsresistentes Prostatakarzinom [mCRPC]), als auch im hormonnaiven Stadium der Erkrankung (metastasiertes kastrationsnaives Prostatakarzinom [mCNPC]). Beim mCNPC verlängerte Docetaxel in Kombination mit der Androgendeprivationstherapie (ADT) die mediane Gesamtüberlebenszeit der Patienten gegenüber der alleinigen ADT um 15 Monate. Vergleichbare Ergebnisse erreichte die endokrine Kombinationstherapie mit ADT/Abirateron. Vor dem Hintergrund der aktuellen Datenlage erscheint es sinnvoll, den Stellenwert der frühen Kombinationstherapie mit ADT/Docetaxel bzw. ADT/Abirateron sowie deren Auswirkungen auf die Folgetherapien beim mCRPC zu diskutieren und Hinweise für den klinischen Alltag zu formulieren.

Abstract

There is an ongoing change of paradigm in the treatment of metastatic prostate cancer (mPC). Taxan-based chemotherapy demonstrated a prolonged survival of patients in several randomized phase III trials. This is true in the situation of metastatic castration-resistent prostate cancer (mCRPC) as well as in the hormone-naïve stage (metastatic castration-naive PC [mCNPC]). In patients with mCNPC, treatment with docetaxel in combination with androgen deprivation therapy (ADT) prolonged the median total survival time by 15 months in comparison to ADT alone. Comparable results were obtained by the endocrine combination treatment with ADT/abiraterone. With the current data in mind it seems to be useful to discuss the value of early combination therapy with ADT/docetaxel or ADT/abiraterone as well as the impact on further treatment options in the mCRPC setting and to define criteria for treatment decisions in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Change history

  • 24 June 2019

    <Emphasis Type="Bold">Erratum zu:</Emphasis>

    <Emphasis Type="Bold">Urologe 2019</Emphasis>

    <ExternalRef><RefSource>https://doi.org/10.1007/s00120-019-0925-2</RefSource><RefTarget Address="10.1007/s00120-019-0925-2" TargetType="DOI"/></ExternalRef>

    Leider ist im englischen Beitragstitel ein Fehler aufgetreten. Wir bitten den korrekten englischen Titel „Treatment situation in metastatic Castration Naive Prostate Cancer (mCNPC) and the implications on clinical routine“ zu beachten

Literatur

  1. Aggarwal R, Harris A, Formaker C et al (2014) Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 12(5):e167–e172

    Article  PubMed  Google Scholar 

  2. Angelergues A, Efstathiou E, Gyftaki R et al (2018) Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor–targeted agents. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2018.02.016

    Article  PubMed  Google Scholar 

  3. Angelergues A, Maillet D, Flechon A et al (2014) Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). JCO Clin Cancer Inform 32(suppl 4):282a

    Google Scholar 

  4. Armstrong A, Garrett-Mayer ES, Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396–6403

    Article  CAS  PubMed  Google Scholar 

  5. Attard G (2017) A phase IV, randomised double-blind placebo-controlled study of continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naïve metastatic castrations-resistant prostate cancer. J Clin Oncol 35(suppl):5004a

    Article  Google Scholar 

  6. Bryce AH, Alumkal JJ, Armstrong A et al (2017) Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 20(2):221–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus Cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  CAS  PubMed  Google Scholar 

  8. De Bono JS, Smith MR, Saad F et al (2017) Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol 71(4):656–664

    Article  CAS  PubMed  Google Scholar 

  9. Deutsche Gesellschaft für Nuklearmedizin e. V. (2016) Therapie mit Lu-177-PSMA, Dosimetrie und Nachsorge beim metastastasierten kastrationsresistenten Prostatakarzinom. Konsensusempfehlung. Version: 01.2016. Stand: 24.02.2016. www.nuklearmedizin.de. Zugegriffen: 12. Mai 2018

    Google Scholar 

  10. Fizazi K, Scher HI, Molina AM et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised double-blind placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992

    Article  CAS  PubMed  Google Scholar 

  11. Fizazi K, Tran NP, Fein L et al (2017) Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

    Article  CAS  PubMed  Google Scholar 

  12. Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158

    Article  CAS  PubMed  Google Scholar 

  13. Gschwend J (2016) SCOPE: nicht-interventionelle prospective Studie zum Einfluss der Behandlungssequenz. Oncol Res Treat 39(suppl 1):87

    Google Scholar 

  14. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomised controlled trial. Lancet 387:1163–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Khalaf D (2018) Phase 2 randomized cross-over trial of abiraterone vs enzalutamide for patients with mCPRC: results for 2nd-line therapy. J Clin Oncol 36(suppl 15s):5015a

    Article  Google Scholar 

  16. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2018) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0, 2018, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom. Zugegriffen: 15. Mai 2018

    Google Scholar 

  17. Maines F, Caffo O, Veccia A et al (2015) Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 96:498–506

    Article  PubMed  Google Scholar 

  18. Maroto P, Solsona E, Gallardo E et al (2016) Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. Crit Rev Oncol Hematol 100:127–136

    Article  PubMed  Google Scholar 

  19. Mezynski J, Pezaro C, Bianchini D et al (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23(11):2943–2947

    Article  CAS  PubMed  Google Scholar 

  20. Miyake H, Hara T, Ozono S et al (2017) Impact of prior use of an androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARTA agent in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15(2):e217–e222

    Article  PubMed  Google Scholar 

  21. Oudard S, de Bono JS, Ozgurolu M et al (2012) Impact of Cabazitaxel + prednisone on overall survival at 2 years and in patients with aggressive disease. Post-hoc analyses of TROPIC trial. Ann Oncol 23(suppl 9):933a

    Google Scholar 

  22. Patrick-Miller L, Chen Y‑H, Carducci MA et al (2016) Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). J Clin Oncol 15(suppl):5004a

    Article  Google Scholar 

  23. Pezaro C, Omlin A, Lorente D et al (2014) Visceral disease in castration-resistant prostate cancer. Eur Urol 65:270–273

    Article  CAS  PubMed  Google Scholar 

  24. Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Scher HI, Fizazi K, Saad PD et al (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 367:1187–1197

    Article  CAS  PubMed  Google Scholar 

  26. Schnadig D, Bhor M, Vogelzang NJ et al (2013) Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). JCO Clin Cancer Inform 31(suppl):79a

    Google Scholar 

  27. Schweizer TS, Zhou XC, Wang H et al (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66(4):646–652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sydes M, Mason MD, Spears MR et al (2017) Adding abiraterone acetate plus prednisone or docetaxel for patients with high-risk prostate cancer starting ling-term androgen deprivation therapy: directly randomised data from STAMPEDE. Orale presentation, ESMO-Jahrestagung 2017, Barcelona

    Google Scholar 

  30. Thibault C, Eymard J‑C, Hardy-Bessard A‑C et al (2017) Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC). JCO Clin Cancer Inform 35(suppl):5033a

    Google Scholar 

  31. Vale CL, Burdett S, Rydzewska LHM et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17(2):243–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Van Soest R, de Morree ES, Shen L et al (2014) Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol 66:330–336

    Article  PubMed  Google Scholar 

  33. Van Soest RJ, Nieuweboer AJ, de Morree ES et al (2015) The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer 51(17):2562–2569

    Article  CAS  PubMed  Google Scholar 

  34. Zhang T, Zhu J, George D et al (2015) Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 16:437–485

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Urologie, Asklepios Klinik Altona, Paul-Ehrlich-Straße 1, 22763, Hamburg, Deutschland

    C. Wülfing

  2. Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland

    M. Bögemann

  3. Urologische und Kinderurologische Klinik, Universitätsklinikum Erlangen, Erlangen, Deutschland

    P. J. Goebell

  4. Klinik für Urologie und Uro-Onkologie, Städtisches Klinikum Braunschweig, Braunschweig, Deutschland

    P. Hammerer

  5. Klinik für Urologie und Kinderurologie, GFO Kliniken Rhein Berg, Betriebsstätte, Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach, Deutschland

    S. Machtens

  6. Klinik für Urologie, Uro-Onkologie, Roboter-assistierte und Spezielle Urologische Chirurgie, Universitätsklinikum Köln, Köln, Deutschland

    D. Pfister

  7. Urologische Klinik, Diakonie-Klinikum Stuttgart, Stuttgart, Deutschland

    C. Schwentner

  8. Martini-Klinik, Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    T. Steuber

  9. Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation, Onkologisches Zentrum, Universitätsklinikum Hamburg, Hamburg, Deutschland

    G. von Amsberg

  10. Klinik für Urologie und Kinderurologie, Universitätsklinik Magdeburg, Magdeburg, Deutschland

    M. Schostak

Authors
  1. C. Wülfing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bögemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. J. Goebell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Hammerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Machtens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Steuber
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. von Amsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Schostak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Wülfing.

Ethics declarations

Interessenkonflikt

C. Wülfing, M. Bögemann, P.J. Goebell, P. Hammerer, S. Machtens, D. Pfister, C. Schwentner, T. Steuber, G. von Amsberg und M. Schostak. geben an, dass kein Interessenkonflikt besteht. Das Expertentreffen, welches als Basis der Publikation diente, wurde organisiert und finanziert von Sanofi-Aventis.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wülfing, C., Bögemann, M., Goebell, P.J. et al. Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag. Urologe 58, 1066–1072 (2019). https://doi.org/10.1007/s00120-019-0925-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-019-0925-2

Schlüsselwörter

Keywords

Search

Navigation